Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06053645

The Weight of Cardiovascular Disease

The purpose of this study is to evaluate the impact of a cardiometabolic clinic on percent body weight loss, body mass index (BMI), and visceral adiposity distribution in obese adults with cardiovascular disease (CVD) at 12 months.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BMI ≥30 kg/m2
  • At least one of the following CVD: atrial fibrillation (AF), coronary artery disease (CAD), HFpEF (heart failure with preserved ejection fraction), HFrEF (heart failure with reduced ejection fraction), ACHD (adult congenital heart disease), or valvular heart disease
  • Patients evaluated in the Cardiometabolic clinic
  • Willingness to complete questionnaires/surveys
  • Ability to complete monthly self-assessments at home

Exclusion criteria

  • BMI <30 kg/m2
  • Pregnancy or lactating women
  • Hemodynamically unstable CVD
  • Active malignancy
  • Autoimmune or systemic inflammatory diseases
  • Severe renal or hepatic failure
  • Being considered unsafe to participate as determined by the study physician
  • Taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic medications, or other medications as determined by the study NP or physician
  • Patients with active psychosis, mania, or substance use disorders

Treatment and study plan

Primary outcomes

  1. Percent body weight loss

    Time frame: 12 months

    Total percent body weight loss will be reported at 12 months based on the following formula: (Starting baseline weight minus current weight) / (starting baseline weight) x 100 equals % of body weight loss.

  2. Change in Body Mass Index (BMI)

    Time frame: Baseline, 12 months

    Body Mass Index (BMI) will be calculated using the standard formula from participants' height and weight. BMI = (Weight in Pounds / (Height in inches x Height in inches)) x 703

  3. Change in visceral adiposity distribution

    Time frame: Baseline, 12 months

    Change in visceral adiposity distribution measured using dual energy X-ray absorptiometry (DEXA).

Secondary outcomes

  1. Change in Blood Pressure

    Time frame: Baseline, 12 months

    Measured in millimeters of mercury (mmHg)

  2. Change in point of care glucose

    Time frame: Baseline, 12 months

    Change in estimated glucose value (mg/dl) obtained from point of care fingerstick testing.

  3. Change in quality of diet

    Time frame: Baseline, 12 months

    Change in quality of diet will be assessed by the Mini-EAT (Eating Assessment Tool). The Mini-EAT is a 9 item questionnaire that asks subjects how often they eat different types of foods (e.g. fruits, vegetables, legumes, etc.). Subjects respond on a scale of "I do not eat it at all" to "6 or more servings per day." Higher scores on the Mini-EAT represent a better quality of diet.

  4. Change in psychosocial distress as measured by Screening Tool for Psychological Distress (STOP-D)

    Time frame: Baseline, 12 months

    Psychosocial distress will be measured by the STOP-D survey. The STOP-D survey asks subjects to rate how often over the last 2 weeks they have felt depressed, anxious, stressed, angry, or lacking social support on a scale of 0-Not at all to 9-Severely. Each item is scored separately without a summed score for overall distress. Higher individual scores on the STOP-D items represent worse psychosocial distress.

  5. Change in psychosocial distress as measured by Impact of Event Scale-Revised (IES-R)

    Time frame: Baseline, 12 months

    Psychosocial distress will be measured by the IES-R. The IES-R is a questionnaire which asks subjects to rate how distressed or bothered during the past seven days they have been by difficulties that people sometimes have after stressful life events. Responses can range from 0-Not at all to 4-Extremely. Items on the questionnaire are grouped into 3 subscales: Intrusion, Avoidance, and Hyperarousal with scores on each subscale being the mean item response of all items in that group, thus scores for each subscale also range from 0 to 4. Higher scores are indicative of more psychosocial distress following the specific life event of focus.

  6. Change in psychosocial distress as measured by Adverse Childhood Experience (ACE) Questionnaire

    Time frame: Baseline, 12 months

    Psychosocial distress will be measured by the ACE Questionnaire. The ACE Questionnaire asks subjects various questions regarding life experiences from the first 18 years of life that may be considered adverse experiences (e.g. parental abuse, neglect, parental divorce, etc.). Subjects answer each question with a yes or no selection. The more questions answered yes represents worse psychosocial distress.

  7. Change in functional aerobic capacity (VO2 Max)

    Time frame: Baseline, 12 months

    VO2 Max is measured as milliliters of oxygen per kilogram of body weight per minute (ml/kg/min) during cardiopulmonary exercise test

  8. Change in artificial intelligence electrocardiogram (AI-ECG) age

    Time frame: Baseline, 12 months

    AI-ECG age is the subject's predicted age based on artificial intelligence analysis of electrocardiograms (ECGs).

  9. Change in E/e'

    Time frame: Baseline, 12 months

    E/e' will be measured using transthoracic echocardiography (TTE). It is defined as the ratio of peak early diastolic mitral inflow velocity (E) and peak early diastolic mitral annular velocity (e') and will be used to assess left ventricular diastolic function.

  10. Change in Peak Tricuspid Regurgitation (TR) Velocity

    Time frame: Baseline, 12 months

    Peak TR Velocity (m/s) will be measured using transthoracic echocardiography (TTE) to assess left ventricular diastolic function.

  11. Change in Right Atrial (RA) Pressure

    Time frame: Baseline, 12 months

    RA pressure (mm Hg) will be measured by transthoracic echocardiography (TTE) to assess left ventricular diastolic function.

  12. Change in Left Atrial (LA) volume index

    Time frame: Baseline, 12 months

    LA volume index (ml/m^2) will be measured by transthoracic echocardiography (TTE) to assess left ventricular diastolic function.

  13. Change in physical activity

    Time frame: Baseline, 12 months

    Average number of steps a subject takes daily as collected by an Apple watch worn by subjects for the duration of the study.

  14. Change in heart rate with detection of arrhythmia

    Time frame: Baseline, 12 months

    Average number of arrhythmias identified by an Apple watch worn by subjects for the duration of the study.

  15. Change in cardio fitness

    Time frame: Baseline, 12 months

    Fitness level reported as high/above average/below average/low as collected by an Apple watch worn by subjects for the duration of the study.

  16. Change in six-minute walk test

    Time frame: Baseline, 12 months

    Measurement (meters) of distance a person can walk on flat ground in 6 minutes collected by an Apple watch worn by subjects for the duration of the study.

  17. Change in psychosocial distress as measured by the Weight Bias Internalization-Modified (WBIS-M) scale

    Time frame: Baseline, 12 months

    The WBIS-M is a 11-item instrument for measuring the extent to which overweight individuals think of themselves in terms of prevalent negative stereotypes about overweight and overweight individuals. Respondents can express their level of agreement on a 7-point Likert scale ranging from 'strongly disagree' (1) to 'strongly agree' (7). Items 1 and 9 need to be scored reversely. Scores are averaged to create a composite score and higher scores represent greater psychosocial distress.

Study contacts

Contact information is provided by the study sponsor or research team.

Kyla Lara-Breitinger, M.D.

CONTACT

[email protected]

(507) 284-4441

Preventive/Vascular Research Team

CONTACT

[email protected]

(507) 538-7425

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Official study title

The Weight of Cardiovascular Disease: A Prospective Pilot Study of Obese Adults With Cardiovascular Disease Evaluated in a Novel Cardiometabolic Clinic

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Sep 26, 2023
Registry last updated
Oct 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.